A Phase I Study to Investigate The Mass Balance and Biotransformation of SIM0417 in Healthy Adult Chinese Male Participants
Latest Information Update: 05 Oct 2022
Price :
$35 *
At a glance
- Drugs Ritonavir (Primary) ; Ritonavir+simnotrelvir (Primary)
- Indications COVID 2019 infections
- Focus Pharmacokinetics
- Sponsors Jiangsu Simcere Pharmaceutical
- 29 Sep 2022 Status changed from not yet recruiting to completed.
- 01 Aug 2022 New trial record